3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Ovarian Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
NSCLC
1
Myeloproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Glioblastoma
1
Bone Marrow Diseases
1
Advanced Solid Tumor
1
Adenocarcinoma of Lung
1
Interventions
Brentuximab Vedotin
13
fludarabine
8
Cyclophosphamide
8
Rituximab
6
ruxolitinib
5
fludarabine phosphate
5
Melphalan
5
Lenalidomide
5
ponatinib
4
Dexamethasone
4
Busulfan
4
Bortezomib
4
nilotinib
3
Whole-Body Irradiation
3
Vincristine
3
Prednisone
3
Mycophenolic Acid
3
Imatinib Mesylate
3
Doxorubicin
3
Bendamustine Hydrochloride
3
Alemtuzumab
3
vosaroxin
2
pomalidomide
2
Tacrolimus
2
Sugars
2
Stem Cell Transplantation
2
Sirolimus
2
Ondansetron
2
Leukapheresis
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hematologic Diseases
×
BID protein, human
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts